Q4FY26 & FY26 Result Announced for Ajanta Pharma Ltd. -

AJANTPHARM

Pharmaceuticals company Ajanta Pharma announced Q4FY26 & FY26 results Q4FY26 Financial Highlights: Revenue from operations at Rs 1,422 crore against Rs 1,170 crore; up 21%. EBITDA at Rs 333 crore against Rs 297 crore; EBITDA at 23%; up 12%. The mark-to-market forex loss stood at Rs 42 crore Excluding this impact, EBITDA stood at Rs 375 crore, reflecting a 26% growth, with an EBITDA margin of 26%. Profit after tax at Rs 267 crore against Rs 225 crore; PAT at 19%; up 18%. FY26 Financial Highlights: Revenue from operations at Rs 5,453 crore against Rs 4,648 crore; up 17%. EBITDA at Rs 1,395 crore against Rs 1,260 crore; EBITDA at 26%; up 11%. The mark-to-market forex loss stood at Rs 103 crore Excluding this impact, EBITDA stood at Rs 1,498 crore, reflecting a 18% growth, with an EBITDA margin of 27%. Profit after tax at Rs 1,056 crore against Rs 920 crore; PAT at 19%; up 15%. ROCE stood at a healthy level of 33% and RONW at 25%. All this is for information. This is not a buy/sell recommendation. Thank you, Technofunda24